RU2584986C2 - Агонисты протеинтирозинфосфатазы-1, содержащей домен гомологии-2 src, и способы лечения с применением указанных агонистов - Google Patents

Агонисты протеинтирозинфосфатазы-1, содержащей домен гомологии-2 src, и способы лечения с применением указанных агонистов Download PDF

Info

Publication number
RU2584986C2
RU2584986C2 RU2014101953/04A RU2014101953A RU2584986C2 RU 2584986 C2 RU2584986 C2 RU 2584986C2 RU 2014101953/04 A RU2014101953/04 A RU 2014101953/04A RU 2014101953 A RU2014101953 A RU 2014101953A RU 2584986 C2 RU2584986 C2 RU 2584986C2
Authority
RU
Russia
Prior art keywords
shp
stat3
optionally substituted
sorafenib
cells
Prior art date
Application number
RU2014101953/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2014101953A (ru
Inventor
Чун-Вай ШИАУ
Куэн-Фэн ЧЭНЬ
Original Assignee
Нэшнл Тайвань Юниверсити
Нэшнл Ян-Мин Юниверсити
ДиСиБи-ЮЭсЭй ЛЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нэшнл Тайвань Юниверсити, Нэшнл Ян-Мин Юниверсити, ДиСиБи-ЮЭсЭй ЛЛС filed Critical Нэшнл Тайвань Юниверсити
Publication of RU2014101953A publication Critical patent/RU2014101953A/ru
Application granted granted Critical
Publication of RU2584986C2 publication Critical patent/RU2584986C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
    • A01N31/14—Ethers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds containing nitrogen-to-oxygen bonds
    • A01N33/18—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Dentistry (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pest Control & Pesticides (AREA)
  • Epidemiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2014101953/04A 2011-08-03 2012-08-03 Агонисты протеинтирозинфосфатазы-1, содержащей домен гомологии-2 src, и способы лечения с применением указанных агонистов RU2584986C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161514555P 2011-08-03 2011-08-03
US61/514,555 2011-08-03
PCT/US2012/049446 WO2013020014A1 (en) 2011-08-03 2012-08-03 Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same

Publications (2)

Publication Number Publication Date
RU2014101953A RU2014101953A (ru) 2015-09-10
RU2584986C2 true RU2584986C2 (ru) 2016-05-27

Family

ID=47629697

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014101953/04A RU2584986C2 (ru) 2011-08-03 2012-08-03 Агонисты протеинтирозинфосфатазы-1, содержащей домен гомологии-2 src, и способы лечения с применением указанных агонистов

Country Status (19)

Country Link
US (1) US9216950B2 (enExample)
EP (1) EP2739139B1 (enExample)
JP (1) JP2014527043A (enExample)
KR (1) KR101661825B1 (enExample)
CN (1) CN104010501B (enExample)
AU (1) AU2012289961C1 (enExample)
BR (1) BR112014002363A2 (enExample)
CA (1) CA2843330C (enExample)
ES (1) ES2762193T3 (enExample)
IL (1) IL230601A (enExample)
IN (1) IN2014MN00125A (enExample)
MX (1) MX353205B (enExample)
MY (1) MY175797A (enExample)
PH (1) PH12014500246A1 (enExample)
PL (1) PL2739139T3 (enExample)
RU (1) RU2584986C2 (enExample)
TW (1) TWI507191B (enExample)
WO (1) WO2013020014A1 (enExample)
ZA (1) ZA201400757B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014032755A2 (en) * 2012-08-29 2014-03-06 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
CN105074467B (zh) * 2013-04-25 2018-06-15 株式会社Cbs生物科学 提高分子靶向治疗肝细胞癌的敏感性的分析方法
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof
HK1248208A1 (zh) * 2015-08-31 2018-10-12 东丽株式会社 尿素衍生物和其用途
CN108026035B (zh) * 2015-09-02 2021-03-30 陈昆锋 具有蛋白酪氨酸磷酸酶shp-1激动剂活性的化合物
US10519113B2 (en) * 2016-08-17 2019-12-31 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds, compositions, and methods of treating cancer
WO2018054354A1 (zh) * 2016-09-22 2018-03-29 陈昆锋 含有src同源区2的蛋白酪氨酸磷酸酶-1激动剂用于改善纤维化的用途
SG11201906671SA (en) * 2017-02-03 2019-08-27 Univ California Compositions and methods for inhibiting reticulon 4
WO2020055755A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN113402456B (zh) * 2020-03-16 2023-03-03 深圳大学 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用
CN112084184B (zh) * 2020-09-15 2022-12-16 青海省地质测绘地理信息院 一种在不同gis平台之间异构数据属性传递的方法
CN120757548A (zh) * 2025-07-01 2025-10-10 遵义医科大学 一种咪唑并[l，2-a]吡啶苯氧基脲类化合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2247109C9 (ru) * 1997-12-22 2005-06-20 Байер Копэрейшн Симметричные и несимметричные производные дифенилмочевины (варианты), фармацевтическая композиция, способ подавления роста опухолевых клеток, опосредованного киназой raf

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1241832B (de) * 1963-02-23 1967-06-08 Hoechst Ag Verfahren zur Herstellung von Pyrimidiniumverbindungen
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
WO1993015043A1 (fr) * 1992-01-24 1993-08-05 Yoshitomi Pharmaceutical Industries, Ltd. Compose arylalkananilide et utilisation pharmaceutique
DK0696585T3 (da) * 1993-04-30 1999-08-23 Yamanouchi Pharma Co Ltd Nyt bisoxadiazolidinderivat
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2376275A1 (en) * 1999-08-20 2001-03-01 Michael John Ricks Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
DE19954312A1 (de) * 1999-11-11 2001-05-17 Bayer Ag Substituierte Phenyluracile
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
JP2007534733A (ja) * 2004-04-26 2007-11-29 アストラゼネカ アクチボラグ 血管損傷剤として使用する３，４−ジ置換マレイミド
SE0401969D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
EP2937345B1 (en) * 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US9029401B2 (en) * 2011-02-14 2015-05-12 The Regents Of The University Of California Sorafenib derivatives as sEH inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2247109C9 (ru) * 1997-12-22 2005-06-20 Байер Копэрейшн Симметричные и несимметричные производные дифенилмочевины (варианты), фармацевтическая композиция, способ подавления роста опухолевых клеток, опосредованного киназой raf

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K.-F. CHEN et al., Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf, EUR. J. MED. CHEM., 2011, Vol. 46, pp.2845-2851. W.-T. TAI et al., Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma, J. HEPATOLOGY, 2011, Vol. 55, pp.1041-1048. *
K.-F. CHEN et al., Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3, CLINICAL CANCER RESEARCH, 2010, Vol. 16, pp.5189-5199. *

Also Published As

Publication number Publication date
PL2739139T3 (pl) 2020-06-15
EP2739139B1 (en) 2019-09-25
TW201320997A (zh) 2013-06-01
KR20140039331A (ko) 2014-04-01
CA2843330C (en) 2016-09-20
US9216950B2 (en) 2015-12-22
AU2012289961C1 (en) 2016-09-01
AU2012289961A1 (en) 2014-02-20
CN104010501B (zh) 2016-05-04
EP2739139A4 (en) 2015-06-10
AU2012289961B2 (en) 2016-05-19
WO2013020014A1 (en) 2013-02-07
KR101661825B1 (ko) 2016-09-30
IN2014MN00125A (enExample) 2015-06-12
EP2739139A1 (en) 2014-06-11
IL230601A (en) 2017-07-31
RU2014101953A (ru) 2015-09-10
ZA201400757B (en) 2015-10-28
MY175797A (en) 2020-07-09
ES2762193T3 (es) 2020-05-22
BR112014002363A2 (pt) 2017-06-13
JP2014527043A (ja) 2014-10-09
IL230601A0 (en) 2014-03-31
CN104010501A (zh) 2014-08-27
CA2843330A1 (en) 2013-02-07
PH12014500246A1 (en) 2014-03-24
NZ620434A (en) 2015-08-28
TWI507191B (zh) 2015-11-11
MX353205B (es) 2018-01-08
MX2014001157A (es) 2015-02-04
US20140200239A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
AU2012289961C1 (en) Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
RU2230551C2 (ru) Ингибиторы th2-дифференцировки
AU2016320073B2 (en) Compound for treating or preventing hyperuricemia or gout
CA3115981A1 (en) Pfkfb3 inhibitors and their uses
TW200916458A (en) Heterocyclic compounds and methods of use thereof
WO2019031472A1 (ja) 新規アントラニル酸系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤
RU2460729C2 (ru) Производные 3-амино-пиридина для лечения метаболических нарушений
WO2014085453A2 (en) Small molecule lxr inverse agonists
US20240132486A1 (en) Rnf4 targeting compounds and uses thereof
US9090617B1 (en) Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
US6255298B1 (en) Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
WO2018189679A1 (en) Isoindoline derivatives for use as ampk activators
JP2003520773A (ja) Ｈｉｖ感染症治療のためのフェニチル−チオウレア化合物
US6124324A (en) Thiophene-ethyl thiourea compounds and use
US11613535B2 (en) Compounds for MYC inhibition
FR2985185A1 (fr) Utilisation en therapeutique de derives d'imidazopyridine
Wang et al. Design, Synthesis, and Antitumor Evaluation of Benzamide Derivatives Targeting HOXA1 Function
NZ620434B2 (en) Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
WO2025174889A1 (en) Malt1 and btk dual inhibitors
US20030125331A1 (en) Cyclohexenyl-ethyl-thiourea compounds and use

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20190903

QB4A Licence on use of patent

Free format text: LICENCE FORMERLY AGREED ON 20190906

Effective date: 20190906

QB4A Licence on use of patent

Free format text: SUB-LICENCE FORMERLY AGREED ON 20200212

Effective date: 20200212